Form 4: Protagonist Therapeutics CMO Sells Shares Under 10b5-1 Plan

Protagonist Therapeutics' Chief Medical Officer, Arturo Molina, MD, reported the sale of 23,151 common shares and the exercise of 10,000 stock options under a pre-arranged 10b5-1 plan.

Summary

• Arturo Molina, MD, Chief Medical Officer of Protagonist Therapeutics, Inc. (PTGX), reported transactions involving the company's common stock and stock options.
• On January 23, 2026, 13,151 shares of common stock were sold at a weighted average price of $82.42 per share.
• On January 26, 2026, 5,000 stock options were exercised at a price of $8.04 per share, and the resulting 5,000 common shares were immediately sold at a weighted average price of $82.28 per share.
• On January 27, 2026, another 5,000 stock options were exercised at a price of $8.04 per share, and the resulting 5,000 common shares were immediately sold at a price of $82.00 per share.
• All reported transactions were made pursuant to a Rule 10b5-1(c) plan, indicating they were pre-scheduled.
• Following these transactions, Arturo Molina, MD, beneficially owns 84,115 shares of common stock and 65,971 stock options.
• The stock options exercised are part of a larger grant of 127,500 shares, with remaining portions vesting monthly through November 7, 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be a negative signal, these transactions were pre-planned under a 10b5-1 plan, mitigating concerns about opportunistic selling. The high sale price relative to the exercise price indicates the insider realized significant gains, reflecting a strong market value for the stock at the time of sale.

Positives

• The sale prices for the common stock were significantly higher than the exercise price of the options ($82+ vs. $8.04), indicating substantial gains for the reporting person.
• The exercise of options suggests the insider saw value in converting options to shares at the time of exercise.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived negatively by the market, although the 10b5-1 plan mitigates this concern.

Future Outlook

Remaining stock options for Arturo Molina, MD, will continue to vest in equal monthly installments through November 7, 2026, subject to continued service to the Issuer.

Industry Context

This filing is a routine disclosure of insider transactions and does not provide specific industry context or trends.

Related Party Transactions

• Arturo Molina, MD, as Chief Medical Officer, engaged in transactions involving the company's securities, which are considered related party transactions.

Stakeholder Impact

• Shareholders may view the insider selling as a routine financial management decision due to the 10b5-1 plan, rather than a signal of diminished confidence in the company's future.
• The significant profit realized by the insider from option exercises and sales could be seen as a positive reflection of the company's stock performance.

Next Steps

• Continued vesting of Arturo Molina, MD's remaining stock options through November 7, 2026.

Key Dates

Recommendation

The insider selling is part of a pre-arranged 10b5-1 plan, which typically signals personal financial management rather than a negative outlook on the company. The high sale price relative to the exercise price indicates the insider is realizing significant gains, which is positive for the individual but neutral for the stock's future prospects. Without further information on company performance or strategic changes, a 'Hold' recommendation is appropriate as this filing alone does not provide a strong buy or sell signal.

Keywords

Protagonist Therapeutics, PTGX, Form 4, insider trading, stock options, share sale, Chief Medical Officer, Arturo Molina, 10b5-1 plan